Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Clinical Trials & Observations

Blood (2020) 135 (24): 2137–2145.

DOI: https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Clinical Trials & Observations

Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven E. Coutre, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour

Blood (2019) 134 (2): 111–122.

DOI: https://doi.org/10.1182/blood.2018882555

Published: 2019

Includes: Supplemental data

Journal Articles

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Clinical Trials & Observations

Courtney D. DiNardo, Keith Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai

Blood (2019) 133 (1): 7–17.

DOI: https://doi.org/10.1182/blood-2018-08-868752

Published: 2019

Includes: Supplemental data

Journal Articles

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Arnon P. Kater, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, MD PhD, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, MD MPH, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 185.

DOI: https://doi.org/10.1182/blood-2018-99-117050

Published: 2018

Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 284.

DOI: https://doi.org/10.1182/blood-2018-99-118729

Published: 2018

Journal Articles

Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

Daniel A Pollyea, MD, Keith W. Pratz, MD, Brian A. Jonas, MD, Anthony Letai, MD PhD, Vinod A. Pullarkat, MD, Andrew Wei, MD, Marina Y. Konopleva, MD PhD, Christian Recher, MD PhD, Olga Frankfurt, MD, David Rizzieri, MD, Tu Xu, PhD, Monique Dail, Brenda Chyla, Jalaja Potluri, MD, Courtney D. DiNardo, MDMSc

Blood (2018) 132 (Supplement 1): 285.

DOI: https://doi.org/10.1182/blood-2018-99-117179

Published: 2018

Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3134.

DOI: https://doi.org/10.1182/blood-2018-99-110183

Published: 2018

Journal Articles

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Clinical Trials & Observations

Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids

Blood (2018) 131 (15): 1704–1711.

DOI: https://doi.org/10.1182/blood-2017-06-788133

Published: 2018

Includes: Supplemental data

Journal Articles

Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies

Sathej Gopalakrishnan, PhD, Brenda Chyla, PhD, Sven Mensing, PhD, Rajeev Menon, PhD, Rod Humerickhouse, MD PhD, Walid Awni, PhD, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD

Blood (2017) 130 (Supplement 1): 4318.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4318.4318

Published: 2017

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Suppl_1): 890.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Brenda Chyla, Relja Popovic, Jalaja Potluri, John Hayslip, Xin Huang, Ming Zhu, Mack Mabry, Anahita Bhathena

Blood (2016) 128 (22): 1709.

DOI: https://doi.org/10.1182/blood.V128.22.1709.1709

Published: 2016

Journal Articles

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Jeffrey Jones, Michael Y. Choi, MD, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, MD, Bruce D. Cheson, Nicole Lamanna, MD, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod A. Humerickhouse, MD, Jalaja Potluri, William G. Wierda, MD PhD, Steven E. Coutre, MD

Blood (2016) 128 (22): 637.

DOI: https://doi.org/10.1182/blood.V128.22.637.637

Published: 2016

Journal Articles

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Andrew W. Roberts, John F Seymour, Barbara Eichhorst, MD, Stephan Stilgenbauer, Michael Y. Choi, MD, Matthew S. Davids, John F. Gerecitano, Relja Popovic, Brenda Chyla, Ming Zhu, Maria Verdugo, Jalaja Potluri, Leanne Lash, Su Young Kim, Michael Hallek

Blood (2016) 128 (22): 3230.

DOI: https://doi.org/10.1182/blood.V128.22.3230.3230

Published: 2016

Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Blood (2015) 126 (23): LBA-6.

DOI: https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6

Published: 2015

Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan

Blood (2015) 126 (23): 2975.

DOI: https://doi.org/10.1182/blood.V126.23.2975.2975

Published: 2015

Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2009) 114 (22): 2374.

DOI: https://doi.org/10.1182/blood.V114.22.2374.2374

Published: 2009

Journal Articles

MTG16, a Target of the T(16;21) in Acute Myeloid Leukemia, Is Required for Hematopoietic Stem and Progenitor Cell Functions

Melissa Ann Steapleton, Isabel Moreno, PhD, Brenda Chyla, PhD, Scott Hiebert, PhD

Blood (2008) 112 (11): 609.

DOI: https://doi.org/10.1182/blood.V112.11.609.609

Published: 2008

NARROW

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

MTG16, a Target of the T(16;21) in Acute Myeloid Leukemia, Is Required for Hematopoietic Stem and Progenitor Cell Functions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only